L&K Biomed

At a glance

L&K Biomed filed 42 disclosures in the last 12 months, including 9 5% holder, 3 insider, 1 issuance and 1 m&a. The most recent key filing was on Oct 16: A major holder's stake rose from 12.22% to 12.31% (related-party change).

Revenue for 2025 was ₩38.9B, up 7.8% on 2024. Operating margin was 1.8% against 8.5% a year earlier. Debt was 116% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩21.2B and operating profit of ₩1.4B.

The 2025 annual report lists 97 employees with an average tenure of 2.7 years and average pay of ₩60.4M, #949 of 1,829 listed companies by average pay. Its 7 directors and auditors were paid ₩127M each on average. It paid no cash dividend for 2025. 강국진 and related parties held 12.21% at year end.

Of 1 recent 5%+ holder report, 1 raised and 0 cut a stake; the largest stake reported was 12.31% on Oct 16.

From the 2025 annual report

Staff: 97 (63 men, 34 women), of whom 0 on fixed-term contracts. Total pay for the year: ₩5.9B. Directors and auditors: 7, paid ₩1B in total.

No cash dividend was paid for 2025.

Largest shareholder

강국진 holds 11.46%; with 6 related parties the group holds 12.21% of common shares at year end (from 13.27% at the start of the year).

Individuals paid ₩500M or more

Auditor: 정동회계법인 · opinion: Unqualified.

Source: 2025 annual business report (DART). How figures are combined

Financial summary

5%+ holder reports